Cargando…

A system dynamics model for national drug policy

BACKGROUND: Data modeling techniques can create a virtual world to analyze decision systems. National drug authorities can use such techniques to take care of their deficiencies in decision making processes. This study was designed to build a system dynamics model to simulate the effects of market m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdollahiasl, Akbar, Kebriaeezadeh, Abbas, Dinarvand, Rassoul, Abdollahi, Mohammad, Cheraghali, Abdol Majid, Jaberidoost, Mona, Nikfar, Shekoufeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229987/ https://www.ncbi.nlm.nih.gov/pubmed/24690531 http://dx.doi.org/10.1186/2008-2231-22-34

Ejemplares similares

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Pharmaceutical supply chain risks: a systematic review
por: Jaberidoost, Mona, et al.
Publicado: (2013)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

Consistent defined threshold and equity in health
por: Nikfar, Shekoufeh, et al.
Publicado: (2015)

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
por: Kebriaeezadeh, Abbas, et al.
Publicado: (2013)

Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
por: Gharibnaseri, Zahra, et al.
Publicado: (2012)

Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods
por: Jaberidoost, Mona, et al.
Publicado: (2015)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Evaluation of prescriptions of medicines not included in Iran medicine list: A cross-sectional study
por: Zargaran, Marzieh, et al.
Publicado: (2016)

Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions
por: Abdollahias, Akbar, et al.
Publicado: (2011)

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
por: Rezvanfar, Mohammad Ali, et al.
Publicado: (2013)

Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study
por: Hashemi Meshkini, Amir, et al.
Publicado: (2012)

“Annual Pharma Statistics” as a Health Information System Application in Iranian Pharmaceutical Sector
por: Farshchi, Amir, et al.
Publicado: (2015)

A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development
por: Goudarzi, Zahra, et al.
Publicado: (2021)

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran
por: Aajami, Zahra, et al.
Publicado: (2019)

A review on inputs and outputs in determining the efficiency of universities of medical sciences by data envelopment analysis method
por: Mojahedian, Mohammad M., et al.
Publicado: (2020)

Implications of Confidential Unit Exclusion in Providing Sufficient Safe Blood for the National Health System
por: Cheraghali, Abdol Majid
Publicado: (2011)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry
por: Cheraghali, Abdol Majid
Publicado: (2012)

Assessment of Influential Variables in the Pricing of Locally Manufactured Pharmaceuticals: Current Challenging Situation in Iran
por: Ashrafi Shahmirzadi, Nikinaz, et al.
Publicado: (2021)

Cost effectiveness of Iran national plasma contract fractionation program
por: Cheraghali, Abdol Majid
Publicado: (2012)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

Policies and measures implemented to reduce the impact of international sanctions on Iran's pharmaceutical sector
por: Emami, Farideh, et al.
Publicado: (2022)

Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran
por: Teimouri, Fatemeh, et al.
Publicado: (2017)

A review of pharmaceutical policies in response to economic crises and sanctions
por: Kheirandish, Mehrnaz, et al.
Publicado: (2015)

Code of ethics for the national pharmaceutical system: Codifying and compilation
por: Salari, Pooneh, et al.
Publicado: (2013)

Pharmacists Remuneration Models in Iran and Selected Countries: a Comparative Study
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Enhanced Oral Delivery of Docetaxel Using Thiolated Chitosan Nanoparticles: Preparation, In Vitro and In Vivo Studies
por: Saremi, Shahrooz, et al.
Publicado: (2013)

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country
por: Ayati, Nayyereh, et al.
Publicado: (2021)

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
por: Rezaie, Ali, et al.
Publicado: (2010)

Are probiotics effective in management of irritable bowel syndrome?
por: Hosseini, Asieh, et al.
Publicado: (2012)

Current opinion on treatment of inflammatory bowel disease in pregnant women
por: Salari, Pooneh, et al.
Publicado: (2012)

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients
por: Mozaffari, Shilan, et al.
Publicado: (2014)

Achieving Equitable Access to Medicines and Health Services: A COVID-19-time Recalled Matter
por: Mousavi, Taraneh, et al.
Publicado: (2021)

Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?
por: Keshavarz, Khosro, et al.
Publicado: (2012)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
por: Mohammad Sadeghi, Hosna, et al.
Publicado: (2021)

Blood safety concerns in the Eastern Mediterranean region
por: Cheraghali, Abdol Majid
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qe7ike4qt2f8jmbim7h1vnkn36